In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
|Articles|January 4, 2022
Novo Holdings to purchase RiteDose
BFS technology deal expected to be finalized in Q1
Advertisement
Novo Holdings A/S, a private limited liability company, has acquired the RiteDose Corporation, a pharma company that specializes in blow-fill-seal (BFS) manufacturing and outsourcing solutions, for an undisclosed amount.
The deal is expected to close in Q1 of this year.
"We are excited and proud to be partnering with Novo Holdings,” notes Jody Chastain, CEO of RiteDose, who will continue to run the contract development and manufacturing organization (CDMO) under Novo Holdings' ownership. “We believe that Novo Holdings' experience and track record in healthcare and their commitment to supporting scientific, humanitarian, and social causes aligns well with our mission and will help us to deliver on our growth aspirations. Our focus has always been on honoring patients and the people who care for them, and we look forward to continuing to do so with Novo Holdings' support."
The past August, RiteDose made
Advertisement
Related to this article
Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.
Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.
Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Supply Chain Signal: How Policy Pressures Are Converging on Pharma
2
Why Temperature Control Is Now Pharma’s Make-or-Break Variable
3
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
4
Copeland Closes Dickson Deal to Expand Cold Chain Monitoring
5